Phathom completes enrollment in Phase 2 EoE trial; topline data expected Q4 2026

Phathom Pharmaceuticals, Inc.

Enrolled 95 adults at 41 US sites in pHalcon-EoE-201 Phase 2 trial of VOQUEZNA for eosinophilic esophagitis.
Patients randomized 1:1 to VOQUEZNA 20 mg or placebo once daily for 12 weeks; optional open-label extension.
Topline results anticipated in Q4 2026; positive data could lead to FDA discussions on pediatric exclusivity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.